Balu Balasubramanian - OUTLOOK THERAPEUTICS Advisor
| OTLK Stock | USD 5.03 0.10 1.95% |
Insider
Balu Balasubramanian is Advisor of OUTLOOK THERAPEUTICS INC
| Address | Building F, Iselin, NJ, United States, 08852 |
| Phone | 609 619 3990 |
| Web | https://www.outlooktherapeutics.com |
OUTLOOK THERAPEUTICS Management Efficiency
The company has return on total asset (ROA) of (0.8369) % which means that it has lost $0.8369 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0365) %, meaning that it created substantial loss on money invested by shareholders. OUTLOOK THERAPEUTICS's management efficiency ratios could be used to measure how well OUTLOOK THERAPEUTICS manages its routine affairs as well as how well it operates its assets and liabilities. At this time, OUTLOOK THERAPEUTICS's Return On Capital Employed is quite stable compared to the past year. Return On Equity is expected to rise to 4.93 this year, although the value of Return On Tangible Assets will most likely fall to (2.20). At this time, OUTLOOK THERAPEUTICS's Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 1.4 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 25.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Barbara Wood | Sellas Life Sciences | 61 | |
| MA MS | Inozyme Pharma | N/A | |
| Chris Storgard | Heron Therapeuti | 58 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Barry PharmD | Heron Therapeuti | 67 | |
| Christine MBA | Hookipa Pharma | 59 | |
| Jay MD | Eyepoint Pharmaceuticals | 65 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| David Jin | Fortress Biotech Pref | 33 | |
| Robyn Hunter | Mustang Bio | 62 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Knut Niss | Mustang Bio | N/A | |
| Bren Kern | Eyenovia | 43 | |
Management Performance
| Return On Equity | -0.0365 | ||||
| Return On Asset | -0.84 |
OUTLOOK THERAPEUTICS INC Leadership Team
Elected by the shareholders, the OUTLOOK THERAPEUTICS's board of directors comprises two types of representatives: OUTLOOK THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OUTLOOK. The board's role is to monitor OUTLOOK THERAPEUTICS's management team and ensure that shareholders' interests are well served. OUTLOOK THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OUTLOOK THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Terry Dagnon, Chief Officer | ||
| Elizabeth Yamashita, Vice President - Regulatory Affairs | ||
| Balu Balasubramanian, Advisor | ||
| Jennifer Kissner, Senior Vice President Clinical Development | ||
| Russell III, CEO President | ||
| Jeffrey Evanson, Chief Officer | ||
| Jedd Comiskey, Senior Europe | ||
| Joel Prieve, VP Operations | ||
| Rick Gregory, Director Communications | ||
| Surendra MD, Senior Affairs | ||
| Lawrence CPA, CFO, VP | ||
| Alicia Tozier, Marketing President | ||
| Ralph Thurman, Executive Chairman of the Board |
OUTLOOK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OUTLOOK THERAPEUTICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0365 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | 119.69 M | ||||
| Shares Outstanding | 23.66 M | ||||
| Shares Owned By Insiders | 35.58 % | ||||
| Shares Owned By Institutions | 35.64 % | ||||
| Number Of Shares Shorted | 3.23 M | ||||
| Price To Earning | (1.24) X | ||||
| Price To Book | 10.19 X | ||||
| Price To Sales | 13.27 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.89) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.